📣 VC round data is live. Check it out!

Bioventus Valuation Multiples

Discover Bioventus' revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Tactile Medical, Polynovo, Sofwave Medical, NeuroPace and more.

Bioventus Overview

About Bioventus

Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.


Founded

2015

HQ

United States

Employees

930

Financials (LTM)

Revenue: $584M
EBITDA: $118M

EV

$786M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Bioventus Financials

Bioventus reported last 12-month revenue of $584M and EBITDA of $118M.

In the same LTM period, Bioventus generated $409M in gross profit, $118M in EBITDA, and $62M in net income.

Revenue (LTM)


Bioventus P&L

In the most recent fiscal year, Bioventus reported revenue of $568M and EBITDA of $116M.

Bioventus is profitable as of last fiscal year, with gross margin of 68%, EBITDA margin of 20%, and net margin of 10%.

See analyst estimates for Bioventus
LTMLast FY202320242025202620272028
Revenue$584M$568M$512M$573M$568M
Gross Profit$409M$388M$328M$388M$388M
Gross Margin70%68%64%68%68%
EBITDA$118M$116M($23M)$39M$99M
EBITDA Margin20%20%(5%)7%17%
EBIT Margin13%13%0%5%10%
Net Profit$62M$59M($156M)($34M)$23M
Net Margin11%10%(30%)(6%)4%
Net Debt-$243M---

Financial data powered by Morningstar, Inc.

Bioventus Stock Performance

Bioventus has current market cap of $549M, and enterprise value of $786M.

Market Cap Evolution


Bioventus' stock price is $8.11.

Bioventus share price decreased by 4.7% in the last 30 days, and increased by 23.5% in the last year.

Bioventus has an EPS (earnings per share) of $0.87.

See more trading valuation data for Bioventus
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$786M$549M2.3%-4.7%-11.2%23.5%$0.87

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Bioventus Valuation Multiples

Bioventus trades at 1.3x EV/Revenue multiple, and 6.7x EV/EBITDA.

See NTM and 2027E valuation multiples for Bioventus

EV / Revenue (LTM)


Bioventus Financial Valuation Multiples

As of June 3, 2026, Bioventus has market cap of $549M and EV of $786M.

Bioventus has a P/E ratio of 8.9x.

LTMLast FY202320242025202620272028
EV/Revenue1.3x1.4x1.5x1.4x1.4x
EV/EBITDA6.7x6.8x(34.1x)20.0x7.9x
EV/EBIT10.3x10.5xn/m30.2x14.0x
EV/Gross Profit1.9x2.0x2.4x2.0x2.0x
P/E8.9x9.4x(3.5x)(16.4x)24.2x
EV/FCF10.2x10.9x98.4x20.8x10.9x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Bioventus Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Bioventus Margins & Growth Rates

Bioventus grew revenue by 7% and EBITDA by 3% in the last fiscal year.

In the most recent fiscal year, Bioventus reported gross margin of 68%, EBITDA margin of 20%, and net margin of 10%.

See estimated margins and future growth rates for Bioventus

Bioventus Margins

Last FY202420252026202720282029
Gross Margin68%68%68%70%
EBITDA Margin20%7%17%20%
EBIT Margin13%5%10%13%
Net Margin10%(6%)4%11%
FCF Margin13%7%13%14%

Bioventus Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth7%12%(1%)7%
Gross Profit Growth10%18%(0%)10%
EBITDA Growth3%(270%)153%20%
EBIT Growth4%1185%116%38%
Net Profit Growth13%(79%)(168%)193%
FCF Growth16%373%91%16%

Data powered by FactSet, Inc. and Morningstar, Inc.

Bioventus Operational KPIs

Bioventus' revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.4M for the same period.

Bioventus' Rule of 40 is 26% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Bioventus' Rule of X is 36% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Bioventus
LTMLast FY202320242025202620272028
Rule of 4027%26%---
Bessemer Rule of X37%36%---
Revenue per Employee-$0.6M---
Opex per Employee-$0.4M---
R&D Expenses to Revenue2%2%3%2%2%
Opex to Revenue-58%64%63%58%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Bioventus Competitors

Bioventus competitors include Tactile Medical, Polynovo, Sofwave Medical, NeuroPace, Cytek Biosciences, Cerus, Japan Lifeline, IBA Group, MiMedx Group and Beta Bionics.

Most Bioventus public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Tactile Medical1.4x1.4x10.6x10.1x
Polynovo5.9x5.0x72.0x57.2x
Sofwave Medical6.0x-68.7x-
NeuroPace5.7x5.7x(114.3x)(86.6x)
Cytek Biosciences1.5x1.5x(463.4x)(186.0x)
Cerus2.4x2.3x58.8x40.6x
Japan Lifeline1.4x1.3x5.8x5.6x
IBA Group0.8x0.8x11.4x10.8x

This data is available for Pro users. Sign up to see all Bioventus competitors and their valuation data.

Start Free Trial

Acquisitions by Bioventus

Bioventus has acquired 4 companies to date.

Last acquisition by Bioventus was on August 30th 2021. Bioventus acquired CartiHeal for $315M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Bioventus

CartiHeal
Misonix
Bioness
BioStructures
Description
CartiHeal is a Herzliya-headquartered medical device company pioneering cartilage regeneration implants. The Agili-C scaffold, implanted arthroscopically, promotes hyaline cartilage formation in knee defects without cells or growth factors. FDA-approved in 2023 following pivotal trials showing superiority over microfracture in 261 patients.
Misonix is a Farmingdale-headquartered medical device company leading in ultrasonic technology for surgical applications. It manufactures aspirators for tissue removal, laparoscopic instruments, bone scalpels, and HIFU systems for tumor ablation. Products like BoneScalpel serve neurosurgery and orthopedics globally since 1982.
Bioness is a medical device company delivering neurostimulation technologies for restoring mobility and hand function in patients with neurological conditions. Headquartered in Valencia, California, with origins in Israel since 2004, Bioness offers the L300 Go System for foot drop correction during gait training and the H200 Wireless System for hand rehabilitation in stroke and spinal cord injury cases. The company's FDA-cleared devices integrate functional electrical stimulation with Bluetooth connectivity and smartphone apps, used in over 5,000 clinics worldwide.
BioStructures is a medical device developer of bioresorbable bone graft products for orthopedic and spinal applications. Its portfolio includes SignaFuse bioactive bone graft putty, OsteoMatrix mineralized collagen scaffolds, and Prohesion hydrolyzed collagen powder for surgical voids. Founded in 2009 and based in Hollister, California, BioStructures supplies customizable allografts and synthetics to surgeons worldwide.
HQ CountryIsraelUnited StatesUnited StatesUnited States
HQ City
Kfar Saba
New York City, NY
-
Los Angeles, CA
Deal Date30 Aug 202129 Jul 202130 Mar 202130 Nov 2015
Valuation$315M$518M$110Mundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Bioventus acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by Bioventus

Bioventus has invested in 3 companies to date.

Latest investment by Bioventus was on August 25th 2021. Bioventus invested in Trice Medical in their $28M Series D round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Bioventus

Trice Medical
Vaporox
CartiHeal
CartiHeal
Description
Trice Medical is a Pennsylvania-based developer of camera-enabled orthopedic diagnostic devices including the SeeTrue needle and miin system for in-office visualization of joints and tissues. Founded in 2011, the company equips physicians with single-use, integrated tools that deliver immediate imaging, reducing reliance on MRI and lowering procedure costs for patients with musculoskeletal conditions.
Vaporox is a Hunt Valley, Maryland-based medical technology company commercializing Vaporous Hyperoxia Therapy, an FDA-510(k)-cleared method treating diabetic foot ulcers, burns, pressure ulcers, gangrene, and skin grafts using patented oxygen delivery.
CartiHeal is a Herzliya-headquartered medical device company pioneering cartilage regeneration implants. The Agili-C scaffold, implanted arthroscopically, promotes hyaline cartilage formation in knee defects without cells or growth factors. FDA-approved in 2023 following pivotal trials showing superiority over microfracture in 261 patients.
CartiHeal is a Herzliya-headquartered medical device company pioneering cartilage regeneration implants. The Agili-C scaffold, implanted arthroscopically, promotes hyaline cartilage formation in knee defects without cells or growth factors. FDA-approved in 2023 following pivotal trials showing superiority over microfracture in 261 patients.
HQ CountryUnited StatesUnited StatesIsraelIsrael
HQ City
Philadelphia, PA
Boston, MA
Kfar Saba
Kfar Saba
Deal Date25 Aug 202124 Jun 202116 Jul 20201 Feb 2018
RoundSeries DStrategic investmentStrategic investmentStrategic investment
Raised$28M$5M$15M$3M
InvestorsBioventusBioventusBioventusBioventus; Peregrine Ventures
Valuationundisclosedundisclosed$195Mundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Bioventus investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Bioventus

When was Bioventus founded?Bioventus was founded in 2015.
Where is Bioventus headquartered?Bioventus is headquartered in United States.
How many employees does Bioventus have?As of today, Bioventus has over 930 employees.
Who is the CEO of Bioventus?Bioventus' CEO is Robert E. Claypoole.
Is Bioventus publicly listed?Yes, Bioventus is a public company listed on Nasdaq.
What is the stock symbol of Bioventus?Bioventus trades under BVS ticker.
When did Bioventus go public?Bioventus went public in 2021.
Who are competitors of Bioventus?Bioventus main competitors include Tactile Medical, Polynovo, Sofwave Medical, NeuroPace, Cytek Biosciences, Cerus, Japan Lifeline, IBA Group, MiMedx Group, Beta Bionics.
What is the current market cap of Bioventus?Bioventus' current market cap is $549M.
What is the current revenue of Bioventus?Bioventus' last 12 months revenue is $584M.
What is the current revenue growth of Bioventus?Bioventus revenue growth (NTM/LTM) is 7%.
What is the current EV/Revenue multiple of Bioventus?Current revenue multiple of Bioventus is 1.3x.
What is the current EBITDA of Bioventus?Bioventus' last 12 months EBITDA is $118M.
What is Bioventus' EBITDA margin?Bioventus' last 12 months EBITDA margin is 20%.
What is the current EV/EBITDA multiple of Bioventus?Current EBITDA multiple of Bioventus is 6.7x.
What is the current FCF of Bioventus?Bioventus' last 12 months FCF is $77M.
What is Bioventus' FCF margin?Bioventus' last 12 months FCF margin is 13%.
What is the current EV/FCF multiple of Bioventus?Current FCF multiple of Bioventus is 10.2x.
How many companies Bioventus has acquired to date?As of June 2026, Bioventus has acquired 4 companies.
What was the largest acquisition by Bioventus?$518M acquisition of Misonix on 29th July 2021 was the largest M&A Bioventus has done to date.
What companies Bioventus acquired?Bioventus acquired Misonix, CartiHeal, Bioness, and BioStructures.
In how many companies Bioventus has invested to date?As of June 2026, Bioventus has invested in 3 companies.
What was the last Bioventus investment?On 25th August 2021 Bioventus invested in Trice Medical, participating in a $28M Series D round.
In what companies Bioventus invested in?Bioventus invested in Trice Medical, CartiHeal, and Vaporox.

See public comps similar to Bioventus

Lists including Bioventus

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial